Prof Michael Hofman, Peter MacCallum Cancer Centre.
Lutetium-177 PSMA radionuclide therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. Lu-PSMA is a radioactive molecule that specifically attaches to cells with high amounts of PSMA on the surface of the cells. This allows the radioactivity to be delivered mainly to the prostate cancer cells wherever they have spread, while sparing most normal tissues. Previous small studies of Lu-PSMA showed promising activity in patients with advanced prostate cancer.
This randomised study will compare Lu-PSMA with a type of chemotherapy called cabazitaxel, which is the standard treatment for advanced prostate cancer when other treatments have stopped working. Half the participants will receive Lu-PSMA and half will receive cabazitaxel. This study will provide further information about the risks and benefits of Lu-PSMA compared with cabazitaxel in men with prostate cancer. Plans are to enrol 200 participants in the study in Australia.
Who is this trial for?
You may be eligible to participate in this trial if you have been diagnosed with metastatic castration resistant prostate cancer for which you have previously received docetaxel. Please talk to your doctor or the trial organisers for more details.
Where is the trial being held?
Peter MacCallum Cancer Centre (open)
The Austin Hospital (estimated to open second quarter 2018)
Monash Medical Centre – Clayton (open)
Monash Medical Centre – Moorabbin of Monash Health (open)
St Vincent’s Hospital (open)
Royal North Shore Hospital (estimated to open second quarter 2018)
Liverpool Hospital (open)
Royal Brisbane and Women’s Hospital (open)
Fiona Stanley Hospital (estimated to open second quarter 2018)
Sir Charles Gairdner Hospital (estimated to open second quarter 2018)
Royal Adelaide Hospital (open)
If you are interested in this study:
Print the details from this form and take to your GP or specialist to discuss the trial.
For more information, please contact:
phone: +61 2 9562 5363